Thomas LaSalle

8PUBLICATIONS
125CO-AUTHORS
Predictive and prognostic markersMolecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 24, 2026
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

|Jan 28, 2026
CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.

Alex C Y Chen, Keely Y Ji, Cansu Yerinde

|Jan 14, 2026
Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.

Avanish Mishra, Catherine B Meador, Kruthika Kikkeri

|Dec 03, 2025
A multimodal atlas of COVID-19 severity identifies hallmarks of dysregulated immunity.

Kamil Slowikowski, Pritha Sen, Christopher V Cosgriff

|Aug 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.

Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle

|May 13, 2022
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.

Marcello Stanzione, Jun Zhong, Edmond Wong

Pageof 2

Frequent Collaborators

6 joint publications

Nir Hacohen

4 joint publications

Moshe Sade-Feldman

3 joint publications

Alexandra-Chloé Villani

3 joint publications

Genevieve M Boland